Brolucizumab for treating wet age-related macular degeneration – guidance (TA672)

Brolucizumab is recommended as an option for treating wet age-related macular degeneration in adults, under certain clinical criteria only

SPS commentary:

The criteria for use are (in the eye to be treated):

  • the best-corrected visual acuity is between 6/12 and 6/96
  • there is no permanent structural damage to the central fovea
  • the lesion size is less than or equal to 12 disc areas in greatest linear dimension and
  • there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).

Brolucizumab should only be continued in people who maintain an adequate response to therapy. Criteria for stopping should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy.

National Institute for Health and Care Excellence